BAC
Bank of America Corporation
BAC's fundamentals are strong: its operating margin rose 5 points to 35% and revenue grew 15%. At 12x earnings, it's trading in line with its usual 13x. Analysts expect earnings growth.
MPT
Medical Properties Trust, Inc.
There isn't enough reported data to score MPT yet.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
MPT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
MPT's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like MPT.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
MPT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 4.2x | $1.71 | — |
| Cheap | 7.1x | $2.90 | +70% |
| Fair | 22x | $8.96 | +424% |
| Expensive | 26x | $10.48 | +513% |
Historical ranges are pointers, not guarantees.
MPT has the edge over BAC in the historical PE scenario, which offers more potential upside but is not a forecast.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over MPT on the outlook, with more favorable earnings and revenue expectations.
MPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Stable | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect MPT's earnings and profitability to decline, with its revenue holding steady.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over MPT on earnings, with more consistent year-over-year improvement.
MPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.41 | +$1.58 |
| Q2 2026 | -$0.06 | +$2.32 |
| Q1 2026 | -$0.21 | +$2.55 |
| Q4 2025 | -$0.46 | +$3.56 |
| Q3 2025 | -$1.17 | +$3.28 |
| Q2 2025 | -$2.38 | +$0.54 |
| Q1 2025 | -$2.76 | -$0.31 |
| Q4 2024 | -$4.02 | -$3.08 |
MPT has returned to profit: it earned $0.41 per share over the past year, after losing money the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over MPT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over MPT on profitability, with a higher operating margin.
MPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $250.1M | +5.3% |
| Q2 2026 | $259.3M | +7.9% |
| Q1 2026 | $252.1M | +13% |
| Q4 2025 | $270.3M | +17% |
| Q3 2025 | $237.5M | +5.2% |
| Q2 2025 | $240.4M | -9.8% |
| Q1 2025 | $223.8M | -18% |
| Q3 2024 | $225.8M | -26% |
MPT's revenue is recovering but still below its 2022 peak: $250M last quarter, up 5.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.5% | -1.9 points |
| Q2 2026 | 3.3% | +0.5 points |
| Q1 2026 | 2.7% | +5.2 points |
| Q4 2025 | 14% | +1.8 points |
| Q3 2025 | -3.6% | +53 points |
| Q2 2025 | 2.9% | -4.6 points |
| Q1 2025 | -2.5% | -21 points |
| Q4 2024 | 12% | N/A |
MPT's operating margin was −5.5% last quarter, down 1.9 points from the same quarter a year ago, near the bottom of its range since 2019.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
MPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $41.1M | +122% |
| Q2 2026 | $62.4M | +21% |
| Q1 2026 | -$14.3M | -3813% |
| Q4 2025 | $160.1M | +109% |
| Q3 2025 | $18.6M | -69% |
| Q2 2025 | $51.7M | +47% |
| Q1 2025 | $384K | -99% |
| Q4 2024 | $76.7M | -43% |
MPT's free cash flow was $249M over the past year, up 69% from the year before. Free cash flow isn't a meaningful measure for financial services companies like MPT.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over MPT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
MPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -799K shares |
| 1 year | -0.7% | -4M shares |
| 3 years | -0.2% | -1.4M shares |
| 5 years | 0% | -158K shares |
| Available history | +21% | +102M shares |
MPT has 597M diluted shares, down 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2023 | $2M |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC has the edge over MPT on leverage, with a lower net debt burden relative to earnings.
MPT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 27.0x | High |
| Q2 2026 | 28.8x | High |
| Q1 2026 | 29.0x | High |
| Q4 2025 | 30.7x | High |
| Q3 2025 | 32.3x | High |
| Q2 2025 | 30.0x | High |
| Q1 2025 | 24.9x | High |
| Q4 2024 | 20.3x | High |
MPT's net debt is more than 20 years of its operating earnings (EBITDA), down from more than 20 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MPT.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
MPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 14.7 | Oversold |
| Stochastic | 2.8 | Oversold |
MPT's weekly RSI is 15 (oversold) and its Stochastic is 3 (oversold).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
MPT PE vs Financial Services Sector
| Metric | MPT | Sector median | Relative |
|---|---|---|---|
| PE | 4.2x | 13x | 68% below |
| PE % | 0 | 63 | 63 pts below |
MPT has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has the edge over MPT on trend strength, trading above more of its moving averages.
MPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.68 | 36% below |
| 20 week MA | $3.65 | 53% below |
| 50 week MA | $4.51 | 62% below |
| 100 week MA | $4.68 | 63% below |
| 200 week MA | $5.44 | 69% below |
MPT is in a downtrend: it's below all five of its weekly moving averages, and 69% below its 200-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has the edge over MPT on returns for 2026, with the stronger performance.
MPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.7 | $21.7 | +4.9% |
| 2021 | $21.7 | $22.7 | +4.3% |
| 2022 | $22.7 | $11.2 | -51% |
| 2023 | $11.2 | $4.91 | -56% |
| 2024 | $4.91 | $3.73 | -24% |
| 2025 | $3.73 | $5.08 | +36% |
| 2026 YTD | $5.08 | $1.71 | -66% |
MPT has finished lower in three of the last six years. It's down 66% so far in 2026.